Publications by authors named "G Banisadr"

Claim this Profile
H
How to dose extended-release carbidopa-levodopa capsules (IPX203, CREXONT®) in patients with Parkinson's disease.
Robert A Hauser, Yasar Torres-Yaghi, Stanley Fisher, Ghazal Banisadr

Clin Park Relat Disord· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duration of "Good On" time per dose: Immediate-release carbidopa-levodopa vs. extended-release carbidopa-levodopa (IPX203, CREXONT®).
R A Hauser, H H Fernandez, J Jimenez-Shahed, S Allard, G Banisadr

Parkinsonism Relat Disord· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of IPX203 in Parkinson's Disease: The RISE-PD Open-Label Extension Study.
Alberto J Espay, Robert A Hauser, Rohit Dhall, Sandeep Thakkar, Leslie Cloud, Ghazal Banisadr

Mov Disord· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical Trial.
Robert A Hauser, Alberto J Espay, Aaron L Ellenbogen, Hubert H Fernandez, Stuart H Isaacson, Ghazal Banisadr

JAMA Neurol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation.
Peter LeWitt, Aaron Ellenbogen, Daniel Burdick, Steven Gunzler, Ramon Gil, Ghazal Banisadr

Clin Park Relat Disord· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis